KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for Aurinia Pharmaceuticals (AUPH) over the last 7 years, with Q3 2025 value amounting to $139.0 million.

  • Aurinia Pharmaceuticals' Shares Outstanding (Diluted Average) fell 459.45% to $139.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.0 million, marking a year-over-year decrease of 459.45%. This contributed to the annual value of $146.2 million for FY2024, which is 206.51% up from last year.
  • Latest data reveals that Aurinia Pharmaceuticals reported Shares Outstanding (Diluted Average) of $139.0 million as of Q3 2025, which was down 459.45% from $140.2 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' 5-year Shares Outstanding (Diluted Average) high stood at $146.2 million for Q4 2024, and its period low was $127.4 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $139.7 million, with a median of $141.9 million in 2022.
  • In the last 5 years, Aurinia Pharmaceuticals' Shares Outstanding (Diluted Average) soared by 1120.4% in 2022 and then plummeted by 459.45% in 2025.
  • Over the past 5 years, Aurinia Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $129.4 million in 2021, then grew by 9.7% to $141.9 million in 2022, then grew by 0.93% to $143.2 million in 2023, then grew by 2.07% to $146.2 million in 2024, then dropped by 4.95% to $139.0 million in 2025.
  • Its last three reported values are $139.0 million in Q3 2025, $140.2 million for Q2 2025, and $143.2 million during Q1 2025.